Capricor Therapeutics (CAPR) Given News Sentiment Score of 0.19

Press coverage about Capricor Therapeutics (NASDAQ:CAPR) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Capricor Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.0032447563219 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Capricor Therapeutics (NASDAQ:CAPR) traded up $0.01 on Thursday, reaching $1.58. The company had a trading volume of 157,600 shares, compared to its average volume of 150,400. The company has a market cap of $40.62, a P/E ratio of -2.39 and a beta of -3.76. Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.25.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $1.00 million. The business’s quarterly revenue was down 58.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) EPS. equities analysts predict that Capricor Therapeutics will post -0.7 EPS for the current fiscal year.

A number of equities analysts have issued reports on the company. ValuEngine upgraded Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. HC Wainwright increased their target price on Capricor Therapeutics from $2.15 to $6.50 and gave the stock a “buy” rating in a research note on Friday, September 15th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Insider Buying and Selling by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply